A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage. RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo. CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Cited by
Items 401–500 of 537
The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered
Ho, C.-T., Kao, W., & Su, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001266
Kakita, N., Jono, M., Tsumuro, H., Satake, S., Iwatani, S., Aoi, K., & Katayama, K. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02185-0 · Cited by 1
Zhou, J., Cheng, Z., Sun, L., & Chen, Z. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s539627
“32 Additionally, thyroid hormone receptorβ selective agonists like resmetirom have shown promise in Phase 3 trials for reducing liver fat content and improving fibrosis.”
de Souza, M. H. G., Al‐Sharif, L., Khalil, S. M., & Diaz, I. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103173
MASLD: Mit GLP-1-Rezeptoragonisten an die Fettleber
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5160-x
(2025) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-025-1599-6
Agonisti multimodali (doppi e tripli agonisti) nel trattamento della diabesità
Capobianco, E., Pippa, F., Garelli, S., & Pagotto, U. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01687-w
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
Diagnostik und Therapie der Grunderkrankung bei Leberzirrhose
Lang‐Meli, J., & Neumann‐Haefelin, C. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_11
Lai, W., Peng, L., Min, J., Qiu, L., Wang, C., Yu, S., Li, Q., Li, R., Jiang, X., & Chen, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665860
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetes aktuell · doi:10.1055/a-2665-1304
Chang, J. Y., & Lee, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70401
Wang, M., Jiang, Y.-N., Li, P., & Wu, Y.-J. (2025) · Systematic Reviews · doi:10.1186/s13643-025-03011-x · Cited by 1
Petroni, M. L. (2025) · The Journal of AMD · doi:10.36171/jamd25.28.3.16
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8383 · Cited by 3
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
“Sur-vodutide, a GLP-1/glucagon receptor co-agonist, was assessed in a phase 2 trial and was shown to achieve MASH improvement in 43–62% and fibrosis improvement in 34– 36% of participants over 48 weeks [36].”
merging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence
Madsbad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v14i1.7208
Cheung, J. T. K., Zhang, X., Wong, G. L., Yip, T. C., Lin, H., Li, G., Leung, H. H. W., Lai, J. C., Mahadeva, S., Mustapha, N. R. N., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.035
Tailleux, A., & Kamel, S. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76568-0
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502639
Chen, X., Nguyen, N., Turner, S. E., Tai, A., Abdelmalek, M. F., Covic, L., & Kuliopulos, A. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101796
“2,8,9 The recent success and provisional approval of the thyroid hormone receptor β agonist resmetirom highlights the potential advantages of exerting pleiotropic effects on multiple pathways involved in MASH pathogenesis, including improving lipid beta-oxidation, glucose homeostasis, inflammation,…”
Sanyal, A. J., Parmar, K., de Oliveira, A. B. S., Jahagirdar, V., & Smirnova, E. (2026) · Research Square · doi:10.21203/rs.3.rs-8342646/v1
Self-citationCarrasco-Sánchez, F. J., Socarrás-Alonso, L., Quintero, C. L., & Oliva‐Pascual‐Vaca, Á. (2026) · Preprints.org · doi:10.20944/preprints202603.0078.v1
Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes
Neeland, I. J., & Baskin, R. L. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00004-5
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
The Future of the Obesity Management Landscape: Challenges, Opportunities and Solutions
Miras, A. D., Kokkinos, A. D., Tahrani, A. A., Reynoso, R., Tomaszewski, J., Lingvay, I., Rubino, D., Purnell, J. Q., Hussain, M., Hall, A., et al. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70127
“…this is the trials on Survodutide for MASH, which has demonstrated at least 30% liver fat reduction in around 60% of participants treated by it compared to 14% treated with placebo together with improvement by at least one fibrosis stage seen in around 34% and 22% participants, respectively [69].”
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
Kumar, S., Macedo, M. P., Roden, M., & Kashyap, S. R. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.003
Rajab, I. M., Emara, A., Rakab, M. S., Azim, A. A. A., Aboeldahab, H. A., Abbas, O. F., Rahman, R. A., & Karagozian, R. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05257-1
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“Regarding metabolic dysfunction-associated steatohepatitis (MASH), liver fat content was reduced up to 30% by servodutide in comparison to placebo [66].”
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01453-y
Metabolische Lebererkrankungen bei Adipositas
Horn, P., & Tacke, F. (2026) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2807-4330
“Ebenso liegen für die Co-Agonisten Tirzepatid und Survodutid bereits vielversprechende Daten zur Verbesserung von Leberentzündung und Leberfibrose aus Phase-2-Studien vor [22, 23], und diese Substanzen befinden sich aktuell in der Phase-3-Prüfung.”
Yang, M., Olaoba, O. T., Chinwo, S., LeVasseur, H. L., Zhou, B., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i14.117396
Bong, S. H. S., Teh, K. K., & Wong, V. W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0125 · Cited by 3
Tesoro, N. A., Rivera, F. B., Bantayan, N. R. B., Magalong, J. V., Tomada, R., Wong, M. A., Tangco, G. A., Pine, P. L. S., Manha, J. K., Tanni, E. S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101623
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
“[56].”
Sun, X., Jiang, H.-L., Ma, Y.-T., Xiong, T.-Q., Leng, X.-Y., Zhao, Y.-F., Shen, X., Zhang, C., & Tang, Y.-J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08219-6 · Cited by 1
“The study revealed that survodutide was the optimal drug for treating patients with MASLD and fibrosis stages of F1– F3 [41, 45] especially in NASH resolution without worsening of fibrosis, fibrosis regression by ≥ 1 stage without worsening of NASH, and MRI-PDFF 30% reduction.”
Hepatic steatosis: A pandemic disease causing serious secondary diseases
Canbay, A., Figge, A., Patsalis, P., Baars, T., Özcürümez, M. K., & Götze, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0074
Zhang, C.-Y., & Yang, M. (2026) · World Journal of Hepatology · doi:10.4254/wjh.120178
Tirzepatide in type 1 diabetes: beyond mere weight loss
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2685653
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“…such as survodutide (glucagon/GLP-1 receptor agonist) have reported high rates of histologic improvement without fibrosis worsening in phase 2 studies, supporting the hypothesis that multi-agonist pharmacology may enhance reductions in liver fat and inflammatory activity in MASH [136, 137].”
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
“Early multi-mechanism approaches are exemplified by the GLP-1R/GIPR/GCGR triple agonist (retatrutide) (Sanyal et al. 2024) and GLP-1R/GCGR dual agonist (survodutide), which extend metabolic debulking beyond GLP-1 monotherapy.”
InfluentialPharmacologic management of metabolic and alcohol-associated liver disease
Pagadala, M., Jalil, S., Dunn, N., & Singal, A. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.29
“These include FGF21 analogs such as efruxifermin and pegozafermin [33] , PPAR agonist lanifibranor [53] , and Survodutide [54] .”
Formulation, Characterization, and Biological Assessment of Embelin-Loaded Glycerosomes
Dhaka, M., Akhter, M. H., & Alsunbul, M. (2026) · Assay and Drug Development Technologies · doi:10.1177/1540658x261449845
Incretin-based therapy for MASH: are two better than one?
Sterling, R. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.74
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Dalt, L. D., Olmastroni, E., Scotti, S., D’Ardes, D., Bianconi, V., D’Onofrio, L., Gioia, L. D., Visco, V., Bencivenga, L., Salis, F., et al. (2026) · European Atherosclerosis Journal · doi:10.56095/eaj.v5i1.135
Ekinci, E. I., Maldonado, S. G., Unseld, A., Arrubla, J., Hennige, A. M., & Schoelch, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70861
Song, L., Hua, S., Zeng, Q., Fu, Y., & Sui, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1844294
“…of the continuously rising global incidence of MASH and the current dilemma of having only one approved drug for treatment (Noureddin et al., 2024; Sanyal et al., 2024; Do et al., 2025), delving deeper into and scientifically elucidating the mechanisms of action of active components in…”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Lee, J.-H., Yoo, J., Kim, S. G., & Kim, Y. S. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0043
Solís, R. S., Baeza-Zapata, A., & Negrete‐Najar, J. P. (2026) · Cureus · doi:10.7759/cureus.111728
“The meta-analysis included three RCTs comprising 695 participants of MASH resolution or histological improvement without worsening of fibrosis [15,16,18].”
InfluentialCiancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
“…drug candidates are being tested in clinical trials for obesity treatment such as survodutide (BI 456906, developed by Zealand/Boehringer-Ingelheim) [52–54], pemvidutide (ALT-801, developed by Altimmune) [55–58], and efinopegdutide (MK-6024, developed by Merck and Hanmi Pharmaceutical) [59,60].”
Drug Development for MASH ‐Related Compensated Cirrhosis: Past, Present and Future
Zeng, R., Shao, Y. C., Lin, R.-T., Shen, X.-T., Sun, Q., Xin, X., Liu, P., Fan, J., Hu, Y., & Feng, Q. (2026) · Liver International · doi:10.1111/liv.70784 · Cited by 2
Metabolism in PTEN hamartoma tumour syndrome
Ambery, P., Bågenholm, R., Pepper, T., Barton, C. M., Whitehead, M. A., Rodriguez, L. H., & Greasley, P. J. (2026) · Metabologia · doi:10.1007/s44357-026-00008-4
“Cotadutide has been shown to deplete both liver fat and liver glycogen (which accumulate in conditions of calorie excess), and survodutide has been shown to significantly reduce hepatic steatosis without worsening of liver fibrosis [151, 152].”
Lawitz, E., Poordad, F. F., & Goodman, Z. D. (2026) · Liver International · doi:10.1111/liv.70808
Self-citationSun, S., Wang, C., Yuan, M., & Min, H. (2026) · Hepatology International · doi:10.1007/s12072-026-11132-1
“Regarding liver fibrosis improvement without worsening steatohepatitis, there was no significant difference after excluding the study by Sanyal et al. [37] The details are shown in Supplementary File 1 Figs.”
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
“Earlier phase 2 work had already shown survodutide produced biopsy-confirmed improvement in metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis [20].”
MASLD: Spatial Mechanisms and New Therapeutics
Stoess, C., Onyuru, J., Hu, Y., Jiang, Y., Xin, Z., Panchal, A., & Hartmann, P. (2026) · Biomolecules · doi:10.3390/biom16081129
“The GLP-1R/glucagon receptor dual agonist survo-dutide also improved MASH without worsening fibrosis and demonstrated reductions in liver fat content, along with favorable fibrosis-related biomarker changes in phase II studies [119].”
Mazdutide and the metabolic treatment revolution
Li, X., Shao, B., Ruan, M., & Yang, S. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.003
Zhou, S., & Dong, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108369
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
Role of glucagon in metabolic diseases
Kitamura, T., Tabei, Y., & Kobayashi, M. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70416
“A phase 2 clinical trial in patients with MASLD/metabolic dysfunction-associated steato-hepatitis demonstrated histological improvement in 62% of patients in the treatment group, compared with 14% in the placebo group, based on liver biopsy analysis 16 .”
Ji, L., Chen, L., Cheng, Z., Lu, Y., Yang, Y., Fu, F., Zhu, Y., Jin, L., & Kloer, I. M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01908-x
“Reductions in LFC and improvements in fibrosis were also demonstrated [27].”
InfluentialCree, M. G., Dunsmoor-Su, R. F., Khoudary, S. R. E., Hurtado, M. D., Kapoor, E., Neal-Perry, G. S., & Santoro, N. F. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100321
“A phase 3 trial of semaglutide and preliminary trials of the OMs tirzepatide and survodutide (a dual glucagon and GLP-1 RA) have shown reductions in metabolic dysfunction – associated steatohepatitis (MASH) [43,64,65].”
Synchronizing obesity management with survodutide
Lonardo, A., & Weiskirchen, R. (2026) · Exploration of Drug Science · doi:10.37349/eds.2026.1008175
Du, Y., Qi, L., Shi, Y., Huang, X., Shi, X., Liu, M., Fang, Y., & Hu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1912000
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“…293 middle-aged individuals with obesity (~ 40% with T2D) with biopsy-proven MASH (fibrosis stages F1–F3) showed significant weight loss, reductions in triglycerides, glycosylated hemoglobin (HbA1c), and hepatic fat content, along with improvement in fibrosis stage without worsening of MASH [44].”
GLP ‐1 Medicines in Perspective: Approaches to Optimize Outcome
Bloomgarden, Z. T. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70264
“Although the agent was associated with a lower mean change in body weight than that expected with the class, changing at Week 76 by just − 12.2%, it led to a 63.1% reduction in liver fat, considerably greater than the 27.8% and 34.0% reductions in total body fat and visceral fat, respectively [7].”
InfluentialZhu, Q., Su, C., 姚巧巧, Yang, T., Xu, Y., Li, M., Liu, Q., Luo, Y., & Yang, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1920121
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
“Fibrosis improvement of at least one stage was achieved in 34%, 36%, and 34% of patients, respectively, compared with 22% in the placebo group [16].”
InfluentialProspects for Use of Incretin Mimetics in Metabolically Associated Fatty Liver Disease
Семикова, Г. В., Khalimov, Y. S., Volkova, A. R., Bystrova, A. A., Pavlova, P. V., & Pozdeeva, M. L. (2026) · Doctor Ru · doi:10.31550/1727-2378-2026-25-3-109-117
Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which
Weglage, J., & Tacke, F. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.60
Therapie metabolischer Lebererkrankungen: Lebensstilintervention, Chirurgie und Pharmakotherapie
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
New therapeutic options for metabolic‐associated steatotic liver disease
Straatmijer, T., & Mulder, M. B. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70795
Xi, J.-Y., Wang, Y.-J., Li, X.-H., Ming, R.-Q., Yan, H.-L., Li, X., Sun, J., Hu, W., Hu, J., Yan, B., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1845959
“Unmeasured factors, including socioeconomic characteristics, dietary quality, medication classes, and genetic traits, may confound the exposure–mediator or mediator–outcome paths and are not addressed by the front-door formula (49–52).”
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Technology and Obesity: A Year in Review
Patra, S., Bhandarkar, A. P., Kapoor, N., & Kalra, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03775-1
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Newsome, P. N., & Ajaz, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70143 · Cited by 2
Self-citationMahajan, N., Kaur, N., Sandhu, S. P. S., Patel, V., Boparai, H. K., Singh, K., & Singh, F. R. (2026) · Cureus · doi:10.7759/cureus.115501
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Incretin-based therapies in hepatology practice
Durmuş, M. E., Köker, G., & Öcal, S. (2026) · World Journal of Hepatology · doi:10.4254/wjh.125275
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
“Improvement in liver fibrosis by at least one stage was observed in approximately one-third of participants receiving the drug, compared to 22% in the placebo group [125].”
The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD
Gallo-Ebert, C., Wayne, J., Brown, A., & Nickels, J. T. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101137
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Liu, H., Zhang, M., & Tacke, F. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s543657
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
“Improvements in MASH without worsening of fibrosis were seen in 47% of participants in the 2.4 mg group, 62% in the 4.8 mg group and 43% in the 6.0 mg group, compared to 14% in the placebo group ( p 0.001) [78].”
InfluentialLu, X., & Li, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1912158
“Survodutide exerts its effect through the dual activation of glucagon receptor and GLP-1 receptor, and while improving liver fibrosis, it also has adverse gastrointestinal reactions (83).”
Passos, P. R. C., Filho, V. O. C., Moraes, B. D. F., Silveira, I. B., SÜFFERT, L. C., & Cançado, G. G. L. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.030
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
“This is true when considering the importance of weight reduction for improvement in OSA, knee osteoarthritis, and, to a lesser extent, MASH.”
InfluentialChirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Endocrine meets hepatic: the thyroid–liver axis in health and disease—an overview
Abdelsamad, H., & Mikosch, P. (2026) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-026-01180-5
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Fujioka, K. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70172
“75,76 Summary and clinical considerations: Be careful what you wish for It is not surprising that one in eight Americans is currently on a GLP ‐ 1 RA for weight loss or comorbid diseases.”
Patoulias, D., Muzurović, E. M., Rizzo, M., & Mantzoros, C. S. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109418
Metadata
- Authors
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., & Younes, R.
- Affiliations
- Inserm (FR)
- From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical Center, Homburg (J.M.S.), and University of the Saarland, Saarbrücken (J.M.S.) — all in Germany; Covenant Metabolic Specialists, Sarasota, FL (G.W.N.); Houston Methodist Hospital and Houston Research Institute, Houston (M.N.), and the Texas Liver Institute, University of Texas Health San Antonio, San Antonio (E.L. and N.A.) — all in Texas; the University of Turin, Turin, Italy (E.B.); the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and Newcastle National Institut...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 311-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399439504
- Cited by
- 528
- References
- 28
- Citations by year
- 2026: 212 · 2025: 237 · 2024: 79
- FWCI
- 159.28
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- survodutide, nonalcoholic steatohepatitis, liver fibrosis, glucagon receptor agonist, GLP-1 receptor agonists, liver fat, histologic improvement, dose-response relationship, adverse events, non-alcoholic fatty liver disease, drug safety and efficacy, dose escalation, maintenance phase
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.